{
    "nctId": "NCT00845910",
    "briefTitle": "A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Evaluating Circulating Endothelial Cell as A Surrogate Marker for Monitoring Treatment Efficacy of Docetaxel Plus Capecitabine With Bevacizumab as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "Overall response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients, 18-65 years of age;\n* locally recurrent and metastatic breast cancer;\n* measurable or evaluable disease;\n* ECOG performance status of 0-2;\n* LVEF \\>=50% without clinical symptoms or signs of heart failure.\n\nExclusion Criteria:\n\n* unknown HER2 status, or known HER2-positive status;\n* prior chemotherapy for locally recurrent or metastatic disease;\n* prior adjuvant or neoadjuvant taxane therapy within 12 months prior to start of treatment;\n* clinical or radiological evidence of CNS metastases;\n* clinically significant cardiovascular disease.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}